In a recent commentary published in The Lancet Infectious Diseases, Charité virologists highlight the potential difficulties of developing vaccines against flaviviruses like dengue or Zika viruses. Application of the first approved dengue virus vaccine CYD-TDV showed that under certain circumstances, antibody-dependent enhancement can lead to severe complications in subsequent dengue infections. As such cross-reactions might occur between different flaviviruses, particularly extensive studies are necessary to ensure the safety of flavivirus vaccines. Jan Felix Drexler works on flavivirus animal reservoirs and diagnostics in the EU-funded project ZIKAlliance.
Back to Overview